{"groups":[{"description":"Participants in all cohorts were administered 20 mg/m\\^2 of Carfilzomib on days +1 and +2, via intravenous catheter (IV) over 30 minutes.\n\nCohort 1: Participants were administered 20 mg/m\\^2 of Carfilzomib on days +6 and +7.\n\nParticipants in all cohorts were administered tacrolimus at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.","id":"FG000","title":"Dose Level 1 - Maximum Dose Carfilzomib 20 mg/m^2"},{"description":"Participants in all cohorts were administered 20 mg/m\\^2 of Carfilzomib on days +1 and +2, via intravenous catheter (IV) over 30 minutes.\n\nCohort 2: Participants were administered 27 mg/m\\^2 of Carfilzomib on days +6 and +7.\n\nParticipants in all cohorts were administered tacrolimus at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.","id":"FG001","title":"Dose Level 2 - Maximum Dose Carfilzomib 27 mg/m^2"},{"description":"Participants in all cohorts were administered 20 mg/m\\^2 of Carfilzomib on days +1 and +2, via intravenous catheter (IV) over 30 minutes.\n\nCohort 3: Participants were administered 36 mg/m\\^2 of Carfilzomib on days +6 and +7.\n\nParticipants in all cohorts were administered tacrolimus at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.","id":"FG002","title":"Dose Level 3 - Maximum Dose Carfilzomib 36 mg/m^2"},{"description":"\"Participants in all cohorts were administered 20 mg/m\\^2 of Carfilzomib on days +1 and +2, via intravenous catheter (IV) over 30 minutes.\n\nCohort 4: Participants were administered 45 mg/m\\^2 of Carfilzomib on days +6 and +7.\n\nParticipants in all cohorts were administered tacrolimus at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.","id":"FG003","title":"Dose Level 4 - Maximum Dose Carfilzomib 45 mg/m^2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"comment":"Started carfilzomib","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"comment":"Completed all 4 doses of Carfilzomib","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase I: Max Dose 20 mg/m^2 (Day 1-7)"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase I: Max Dose 27 mg/m^2 (Day 1-7)"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase I: Max Dose 36 mg/m^2 (Day 1-7)"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Phase I: Max Dose 45 mg/m^2 (Day 1-7)"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"37"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"36"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase II: Max Dose 36 mg/m^2 (Day 1-7)"}],"preAssignmentDetails":"Two patients who consented never began treatment."}